Safety of Tocilizumab on Rheumatoid Arthritis in Patients with Interstitial Lung Disease

References

• Mori S, Koga Y, Sugimoto M. Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Respir Med. 2012;106:1591–1599.
   PubMed Web of Science ®Google Scholar
• Olson AL, Swigris JJ, Sprunger DB, et al. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med. 2011;183(3):372–378. doi:10.1164/rccm.201004-0622OC
   PubMed Web of Science ®Google Scholar
• Shidara K, Hoshi D, Inoue E, et al. Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort, IORRA. Mod Rheumatol. 2010;20(3):280–286. doi:10.3109/s10165-010-0280-z
   PubMed Web of Science ®Google Scholar
• Bongartz T, Nannini C, Medina‐Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62(6):1583–1591. doi:10.1002/art.27405
   PubMed Web of Science ®Google Scholar
• Tsuchiya Y, Takayanagi N, Sugiura H, et al. Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J. 2011;37(6):1411–1417. doi:10.1183/09031936.00019210
   PubMed Web of Science ®Google Scholar
• Koduri G, Norton S, Young A, et al. ERAS (Early Rheumatoid Arthritis Study). Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology. 2010;49(8):1483–1489. doi:10.1093/rheumatology/keq035
   PubMed Web of Science ®Google Scholar
• Onda K, Honma T, Masuyama K. Methotrexate-related adverse events and impact of concomitant treatment with folic acid and tumor necrosis factor-alpha inhibitors: an assessment using the FDA adverse event reporting system. Front Pharmacol. 2023;14:1030832. doi:10.3389/fphar.2023.1030832
   PubMed Web of Science ®Google Scholar
• Hozumi H, Nakamura Y, Johkoh T, et al. Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: a retrospective case control study. BMJ Open. 2013; 3:e003132.
   PubMed Web of Science ®Google Scholar
• Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology. 2004;43(2):143–147. doi:10.1093/rheumatology/keg466
   PubMed Web of Science ®Google Scholar
• Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ. Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheumatol. 2014;66(4):803–812. doi:10.1002/art.38322
   PubMed Web of Science ®Google Scholar
• Kim YJ, Song M, Ryu JC. Inflammation in methotrexate-induced pulmonary toxicity occurs via the p38 MAPK pathway. Toxicology. 2009;256(3):183–190. doi:10.1016/j.tox.2008.11.016
   PubMed Web of Science ®Google Scholar
• Cho I, Mori S, Imamura F, Kiyofuji C, Sugimoto M. Methotrexate pneumonia lacking dyspnea and radiographic interstitial patterns during treatment for early rheumatoid arthritis: bronchoalveolar lavage and transbronchial lung biopsy in a differential diagnosis. Mod Rheumatol. 2007;17(3):256–261. doi:10.3109/s10165-007-0578-7
   PubMedGoogle Scholar
• Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis. 2009;68(7):1100–1104. doi:10.1136/ard.2008.093690
   PubMed Web of Science ®Google Scholar
• Mochizuki T, Yano K, Ikari K, Okazaki K. Radiological evaluation of interstitial lung disease in patients with rheumatoid arthritis treated with Abatacept or JAK inhibitors for 1 year. Respir Investig. 2023;61(3):359–363. doi:10.1016/j.resinv.2023.02.007
   PubMed Web of Science ®Google Scholar
• Mena-Vázquez N, Rojas-Gimenez M, Fuego-Varela C, et al. Fernández-Nebro, A. Safety and effectiveness of Abatacept in a prospective cohort of patients with rheumatoid arthritis-associated interstitial lung disease. Biomedicines. 2022;10(7):1480. doi:10.3390/biomedicines10071480
   PubMed Web of Science ®Google Scholar
• Nakashita T, Ando K, Kaneko N, Takahashi K, Motojima S. Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis. BMJ Open. 2014; 4(8): e005615. doi:10.1136/bmjopen-2014-005615
   PubMed Web of Science ®Google Scholar
• Mena-Vázquez N, Godoy-Navarrete FJ, Manrique-Arija S, et al. Non-anti-TNF biologic agents are associated with slower worsening of interstitial lung disease secondary to rheumatoid arthritis. Clin Rheumatol. 2021;40(1):133–142. doi:10.1007/s10067-020-05227-9
   PubMed Web of Science ®Google Scholar
• Narváez J, Díaz Del Campo Fontecha P, Brito García N, et al. SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 2: treatment. Reumatol Clin. 2022;18(9):501–512. doi:10.1016/j.reuma.2022.03.005
   PubMed Web of Science ®Google Scholar
• Le TT, Karmouty-Quintana H, Melicoff E, et al. Blockade of IL-6 trans signaling attenuates pulmonary fibrosis. J Immunol. 2014;193(7):3755–3768. doi:10.4049/jimmunol.1302470
   PubMed Web of Science ®Google Scholar
• Hadjinicolaou AV, Nisar MK, Bhagat S, Parfrey H, Chilvers ER, Ostör AJ. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review. Rheumatology. 2011;50(12):2297–2305. doi:10.1093/rheumatology/ker289
   PubMed Web of Science ®Google Scholar
• Luppi F, Sebastiani M, Salvarani C, Bendstrup E, Manfredi A. Acute exacerbation of interstitial lung disease associated with rheumatic disease. Nat Rev Rheumatol. 2022;18(2):85–96. doi:10.1038/s41584-021-00721-z
   PubMed Web of Science ®Google Scholar
• Reynisdottir G, Karimi R, Joshua V, et al. Structural changes and antibody enrichment in the lungs are early features of anti-citrullinated protein antibody-positive rheumatoid arthritis. Arthritis Rheumatol. 2014;66(1):31–39. doi:10.1002/art.38201
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Matsuda Y, Tanaka M, et al. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum. 2000;43(4):852–858. doi:10.1002/1529-0131(200004)43:4<852::AID-ANR16>3.0.CO;2-7
   PubMed Web of Science ®Google Scholar
• Yokoyama A, Kondo K, Nakajima M, et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology. 2006;11(2):164–168. doi:10.1111/j.1440-1843.2006.00834.x
   PubMed Web of Science ®Google Scholar
• Kato E, Sawada T, Tahara K, et al. The age at onset of rheumatoid arthritis is increasing in Japan: a nationwide database study. Int J Rheum Dis. 2017;20(7):839–845. doi:10.1111/1756-185X.12998
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Sugiyama N, Inoue E, Taniguchi A, Momohara S. Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I). Mod Rheumatol. 2014;24(1):33–40. doi:10.3109/14397595.2013.854059
   PubMed Web of Science ®Google Scholar
• Pavlov-Dolijanovic S, Bogojevic M, Nozica-Radulovic T, Radunovic G, Mujovic N. Elderly-onset rheumatoid arthritis: characteristics and treatment options. Medicina. 2023;59(10):1878. doi:10.3390/medicina59101878
   PubMedGoogle Scholar
• Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin. Arthritis Rheum. 2011;41:256–264.
   Google Scholar
• Boleto G, Guignabert C, Pezet S, et al. T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis. Arthritis Res Ther. 2018;20(1):197. doi:10.1186/s13075-018-1694-9
   PubMedGoogle Scholar
• Skeoch S, Weatherley N, Swift AJ, et al. Drug-induced interstitial lung disease: a systematic review. J Clin Med. 2018;7(10):356. doi:10.3390/jcm7100356
   PubMed Web of Science ®Google Scholar
• Cafaro G, Alunno A, Valentini V, et al. The onset site of rheumatoid arthritis: the joints or the lung? Reumatismo. 2016;68(4):167–175. doi:10.4081/reumatismo.2016.892
   PubMedGoogle Scholar